B Lynne Parshall - Net Worth and Insider Trading
B Lynne Parshall Net Worth
The estimated net worth of B Lynne Parshall is at least $4 Million dollars as of 2024-11-05. B Lynne Parshall is the Director of Ionis Pharmaceuticals Inc and owns about 82,588 shares of Ionis Pharmaceuticals Inc (IONS) stock worth over $3 Million. B Lynne Parshall is the Director of Cytokinetics Inc and owns about 20,600 shares of Cytokinetics Inc (CYTK) stock worth over $1 Million. B Lynne Parshall is also the Director, 10% Owner of Regulus Therapeutics Inc and owns about 58,746 shares of Regulus Therapeutics Inc (RGLS) stock worth over $86,650. Details can be seen in B Lynne Parshall's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that B Lynne Parshall has not made any transactions after 2024-09-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of B Lynne Parshall
B Lynne Parshall Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, B Lynne Parshall owns 6 companies in total, including Akcea Therapeutics Inc (AKCA) , Cytokinetics Inc (CYTK) , and Ionis Pharmaceuticals Inc (IONS) among others .
Click here to see the complete history of B Lynne Parshall’s form 4 insider trades.
Insider Ownership Summary of B Lynne Parshall
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AKCA | Akcea Therapeutics Inc | 2020-10-12 | director |
| CYTK | Cytokinetics Inc | 2024-09-09 | director |
| IONS | Ionis Pharmaceuticals Inc | 2023-12-28 | director & Executive Vice President & CFO |
 | | 2012-10-10 | director & 10 percent owner |
| | 2006-05-11 | director |
| | 2022-08-16 | director |
B Lynne Parshall Latest Holdings Summary
B Lynne Parshall currently owns a total of 3 stocks. Among these stocks, B Lynne Parshall owns 82,588 shares of Ionis Pharmaceuticals Inc (IONS) as of December 28, 2023, with a value of $3 Million and a weighting of 73.25%. B Lynne Parshall owns 20,600 shares of Cytokinetics Inc (CYTK) as of September 9, 2024, with a value of $1 Million and a weighting of 24.73%. B Lynne Parshall also owns 58,746 shares of Regulus Therapeutics Inc (RGLS) as of October 10, 2012, with a value of $86,650 and a weighting of 2.02%.
Latest Holdings of B Lynne Parshall
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IONS | Ionis Pharmaceuticals Inc | 2023-12-28 | 82,588 | 38.05 | 3,142,060 |
| CYTK | Cytokinetics Inc | 2024-09-09 | 20,600 | 51.49 | 1,060,591 |
| RGLS | Regulus Therapeutics Inc | 2012-10-10 | 58,746 | 1.48 | 86,650 |
Holding Weightings of B Lynne Parshall
B Lynne Parshall Form 4 Trading Tracker
According to the SEC Form 4 filings, B Lynne Parshall has made a total of 5 transactions in Ionis Pharmaceuticals Inc (IONS) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Ionis Pharmaceuticals Inc is the sale of 117,638 shares on December 28, 2023, which brought B Lynne Parshall around $6 Million.
According to the SEC Form 4 filings, B Lynne Parshall has made a total of 13 transactions in Cytokinetics Inc (CYTK) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Cytokinetics Inc is the sale of 5,000 shares on September 9, 2024, which brought B Lynne Parshall around $274,600.
According to the SEC Form 4 filings, B Lynne Parshall has made a total of 0 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years. The most-recent trade in Regulus Therapeutics Inc is the acquisition of 6,250 shares on October 10, 2012, which cost B Lynne Parshall around $3 Million.
Insider Trading History of B Lynne Parshall
- 1
B Lynne Parshall Trading Performance
GuruFocus tracks the stock performance after each of B Lynne Parshall's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by B Lynne Parshall is 36.87%. GuruFocus also compares B Lynne Parshall's trading performance to market benchmark return within the same time period. The performance of stocks bought by B Lynne Parshall within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how B Lynne Parshall's insider trading performs compared to the benchmark.
Performance of B Lynne Parshall
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.31 | | | | | |
| Relative Return to S&P 500(%) | 21.99 | | | | | |
B Lynne Parshall Ownership Network
Ownership Network List of B Lynne Parshall
Ownership Network Relation of B Lynne Parshall
B Lynne Parshall Owned Company Details
What does Akcea Therapeutics Inc do?
Who are the key executives at Akcea Therapeutics Inc?
B Lynne Parshall is the director of Akcea Therapeutics Inc. Other key executives at Akcea Therapeutics Inc include director & Chief Executive Officer Damien Mcdevitt , Chief Medical Officer William T. Andrews , and Chief Financial Officer Michael Dennis Price .
Akcea Therapeutics Inc (AKCA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akcea Therapeutics Inc (AKCA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akcea Therapeutics Inc (AKCA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akcea Therapeutics Inc (AKCA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akcea Therapeutics Inc Insider Transactions
B Lynne Parshall Mailing Address
Above is the net worth, insider trading, and ownership report for B Lynne Parshall. You might contact B Lynne Parshall via mailing address: 2855 Gazelle Court, Carlsbad Ca 92010.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
